Alexander Eggermont, MD, PhD, of Gustave Roussy, discusses final overall survival findings on ipilimumab vs placebo after complete resection of stage III melanoma. (Abstract LBA2)
Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses in German study findings on neoadjuvant ipilimumab plus nivolumab in patients with palpable stage III melanoma. (Abstract LBA39)
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses study findings on cabozantinib vs sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor and intermediate risk. (Abstract LBA30) Follow him on Twitter: @DrChoueiri
Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori–Fondazione Pascale, discusses overall survival and safety results from a phase III trial of ipilimumab at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma. (Abstract 1106O)
Katja Weisel, MD, of the University of Tübingen, discusses study findings on daratumumab, bortezomib, and dexamethasone vs bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. (Abstract 906O)
Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses study findings on neoadjuvant ipilimumab plus nivolumab in patients with palpable stage III melanoma. (Abstract LBA39)
